Characterization of bropirimine O-glucuronidation in human liver microsomes

References

• BERTZ, R. J. and GRANNEMAN, G. R., 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210–258.
   PubMed Web of Science ®Google Scholar
• BOERSMA, M. G., VAN DER WOUDE, H., BOGAARDS, J., BOEREN, S., VERVOORT, J., CNUBBEN, N. H., VAN TEASEL, M. L., VAN BLADEREN, P. J. and RIETJENS, I. M., 2002, Regioselectivity of Phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chemical Research in Toxicology, 15, 662–670.
   PubMed Web of Science ®Google Scholar
• BURCHELL, B., NEBERT, D. W., NELSON, D. R., BOCK, K. W., IYANAGI, T., JANSEN, P. L., LANCET, D., MULDER, G. J., CHOWDHURY, J. R. and SIEST, G., 1991, The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biology, 10, 487–494.
   PubMed Web of Science ®Google Scholar
• CIOTTI, M., MARRONE, A., POTTER, C. and OWENS, I. S., 1997, Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics, 7, 485–495.
   PubMedGoogle Scholar
• COURT, M. H., DUAN, S. X., VON MOLTKE, L. L., GREENBLATT, D. J., PATTEN, C. J., MINERS, J. 0. and MACKENZIE, P. I., 2001, Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. Journal of Pharmacology and Experimental Therapeutics, 299, 998–1006.
   Google Scholar
• EBNER, T. and BURCHELL, B., 1993, Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metabolism and Disposition, 21, 50–55.
   PubMed Web of Science ®Google Scholar
• EBNER, T., REMMEL, R. P. and BURCHELL, B., 1993, Human bilirubin UDP-glucuronosyltransferase catalyses the glucuronidation of ethinylestradiol. Molecular Pharmacology, 43, 649–654.
   PubMed Web of Science ®Google Scholar
• ETHELL, B. T., EKINS, S., WANG, J. and BURCHELL, B., 2002, Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metabolism and Disposition, 30, 734–738.
   PubMed Web of Science ®Google Scholar
• FISHER, M. B., VANDENBRANDEN, M., FINDLAY, K., BURCHELL, B., THUMMEL, K. E., HALL, S. D., WRIGHTON, S. A., 2000, Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics, 10, 727–739.
   PubMedGoogle Scholar
• GAGNE, J. F., MONTMINY, V., BELANGER, P., JOURNAULT, K., GAUCHER, G. and GUILLEMETTE, C., 2002, Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Molecular Pharmacology, 62, 608–617.
   PubMed Web of Science ®Google Scholar
• GREEN, M. D., BISHOP, W. P. and TEPHLY, T. R., 1995, Expressed human UGT1.4 protein catalyses the formation of quaternary ammonium-linked glucuronides. Drug Metabolism and Disposition, 23, 299–302.
   PubMed Web of Science ®Google Scholar
• GREEN, M. D., KING, C. D., MOJARRABI, B., MACKENZIE, P. I. and TEPHLY, T. R., 1998, Glucuronidation of amines and other xenobiotics catalysed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metabolism and Disposition, 26, 507–512.
   PubMed Web of Science ®Google Scholar
• HAGENAUER, B., SALAMON, A., THALHAMMER, T., KUNERT, 0., HASLINGER, E., KLINGLER, P., SENDEROWICZ, A. M., SAUSVILLE, E. A. and JAGER, W., 2001, In vitro glucuronidation of the cyclin-dependent kinase inhibitor fiavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metabolism and Disposition, 29, 407–414.
   Google Scholar
• HALPIN, R. A., PORRAS, A. G., GEER, L. A., DAVIS, M. R., Cm, D., Doss, G. A., WOOLF, E., MUSSON, D., MATTHEWS, C., MAZENKO, R., SCHWARTZ, J. I., LASSETER, K. C., VYAS, K. P. and BAILLIE, T. A., 2002, The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metabolism and Disposition, 30, 684–693.
   PubMed Web of Science ®Google Scholar
• HAUER, M. J., THORNBURGH, B. A., EAGERNESS, P. E., WIENKERS, L. C., VRBANAC, J. J. and WICKREMA SINHA, A. J., 1997, Identification of the major urinary metabolites of bropirimine following oral administration of [14C]bropirimine to healthy human volunteers. Proceedings of the 8th North American ISSX Meeting, Hilton Head, SC, Abstract 219, October 1997.
   Google Scholar
• IYER, L., MORTELL, M. A., YAMAMOTO, Y., AZUMA, R. and RATAIN, M. J., 1998, Glucuronidation of TAS-103 by uridine diphosphate glucuronosyltransferase (UGT) isoforms 1A1 and 2: possible implication of TAS-103 toxicity in Gilbert's syndrome (Abstract). Annals of Oncology, 9, 61.
   Web of Science ®Google Scholar
• KADAKOL, A., GHOSH, S. S., SAPPAL, B. S., SHARMA, G., CHOWDHURY, J. R. and CHOWDHURY, N. R., 2000, Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler—Najjar and Gilbert syndromes: correlation of genotype to phenotype. Human Mutation, 16, 297–306.
   PubMed Web of Science ®Google Scholar
• KEMR, D. C., FAN, P. W. and STEVENS, J. C., 2002, Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metabolism and Disposition, 30, 694–700.
   PubMed Web of Science ®Google Scholar
• KING, C. D., GREEN, M. D., Rios, G. R., COFFMAN, B. L., OWENS, I. S., BISHOP, W. P. and TEPHLY, T. R., 1996, The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Archives of Biochemistry and Biophysics, 332, 92–100.
   PubMed Web of Science ®Google Scholar
• LEVESQUE, E., BEAULIEU, M., Hum, D. W. and BELANGER, A., 1999, Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics, 9, 207–216.
   PubMedGoogle Scholar
• LUUKKANEN, L., MIKKOLA, J., FORSMAN, T., TAAVITSAINEN, P., TASKINEN, J. and ELOVAARA, E., 2001, Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: development of a high-sensitivity glucuronidation assay for human tissue. Drug Metabolism and Disposition, 29, 1096–1101.
   PubMed Web of Science ®Google Scholar
• MACKENZIE, P. I., OWENS, I. S., BURCHELL, B., BOCK, K. W., BAIROCH, A., BELANGER, A., FOURNEL-GIGLEUX, S., GREEN, M., Hum, D. W., IYANAGI, T., LANCET, D., LOUISOT, P., MAGOALOU, J., CHOWDHURY, J. R., RITTER, J. K., SCHACHTER, H., TEPHLY, T. R., TIPTON, K. F. and NEBERT, D. W., 1997, The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7, 255–269.
   Google Scholar
• McGuRE, K. A., BRIERLEY, C. H. and BURCHELL, B., 1998, Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochemical Pharmacology, 55, 1005–1012.
   PubMed Web of Science ®Google Scholar
• McGuRE, K. A., REMMEL, R. P., HOSAGRAHARA, V. P., TOSH, D. and BURCHELL, B., 1996, Reactivity of mefenamic acid 1-0-acyl glucuronide with proteins in vitro and ex vivo. Drug Metabolism and Disposition, 24, 842–849.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA, M., TANAKA, E., KOBAYASHI, T., OHASHI, N., KUME, T. and YOKOI, T., 2002, Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metabolism and Disposition, 30, 636–642.
   PubMed Web of Science ®Google Scholar
• OWENS, I. S. and RITTER, J. K., 1995, Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Progress in Nucleic Acids Research and Molecular Biology, 51, 305–338.
   PubMed Web of Science ®Google Scholar
• RITTER, J. K., 2000, Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chemico-Biological Interactions, 129, 171–193.
   PubMed Web of Science ®Google Scholar
• SAROSDY, M. E., LAMM, D. L., WILLIAMS, R. D., MOON, T. D., FLANIGAN, R. C., CRAWFORD, E. D., WILKS, N. E., EARHART, R. H. and MERRITT, J. A., 1992, Phase 1 trail of oral bropirimine in superficial bladder cancer. Journal of Urology, 147, 31–34.
   PubMed Web of Science ®Google Scholar
• SEPPEN, J., BOSMA, P. J., GOLDHOORN, B. G., BAKKER, C. T., CHOWDHURY, J. R., CHOWDHURY, N. R., JANSEN, P. L. and OUDE ELFERINK, R. P., 1994, Discrimination between Crigler—Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. Journal of Clinical Investigation, 94, 2385–2391.
   PubMed Web of Science ®Google Scholar
• SORICH, M. J., SMITH, P. A., MCKINNON, R. A. and MINERS, J. 0., 2002, Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics, 12, 635–645.
   Google Scholar
• TAKENAGA, N., Ism', M., KAMEI, T. and YASUMORI, T., 2002, Structure—activity relationship in o-glucuronidation of indolocarbazole analogs. Drug Metabolism and Disposition, 30, 494–497. TEPHLY, T. R. and BURCHELL, B., 1990, UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends in Pharmacological Science, 11, 276–279.
   Google Scholar
• THRASHER, J. B. and CRAWFORD, E. D., 1993, Current management of invasive and metastatic cell carcinoma of the bladder. Journal of Urology, 149, 957–972.
   PubMed Web of Science ®Google Scholar
• TUKEY, R. H. and STRASSBURG, C. P., 2000, Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual Reviews in Pharmacology and Toxicology, 40, 581–616.
   PubMed Web of Science ®Google Scholar
• WIENKERS, L. C., STEENWYK, R. C., SANDERS, P. E. and PEARSON, P. G., 1996, Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 982–990.
   PubMed Web of Science ®Google Scholar
• WYNALDA, M. A., HAUER, M. J. and WIENKERS, L. C., 1998, Human biotransformation of bropirimine. characterization of the major bropirimine oxidative metabolites formed in vitro. Drug Metabolism and Disposition, 26, 1048–1051.
   PubMed Web of Science ®Google Scholar
• ZHENG, Z., FANG, J. L. and LAZARUS, P., 2002, Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metabolism and Disposition, 30, 397–403.
   PubMed Web of Science ®Google Scholar
• ZHOU, H. H., SHELLER, J. R., Nu, H., WOOD, M. and WOOD, A. J., 1993, Ethnic differences in response to morphine. Clinical and Pharmacological Therapy, 54, 507–513.
   PubMed Web of Science ®Google Scholar